Treating major depression in congestive heart failure: An open-label trial of nefazodone

1999 ◽  
Vol 5 (3) ◽  
pp. 61 ◽  
Author(s):  
Francois Lesperance ◽  
Nancy Frasure-Smith ◽  
Michel White ◽  
Jean-Lucien Rouleau
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Major Depression ◽  
Open Label ◽  
Open Label Trial

An Open-Label Study of Nefazodone Treatment of Major Depression in Patients with Congestive Heart Failure

2003 ◽  
Vol 48 (10) ◽  
pp. 695-701 ◽  
Author(s):  
François Lespérance ◽  
Nancy Frasure-Smith ◽  
Marc-André Laliberté ◽  
Michel White ◽  
Sylvain Lafontaine ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Major Depression ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression

2004 ◽  
Vol 161 (1) ◽  
pp. 171-174 ◽  
Author(s):  
Carlos A. Zarate ◽  
Jennifer L. Payne ◽  
Jorge Quiroz ◽  
Jonathan Sporn ◽  
Kirk K. Denicoff ◽  
...  
Keyword(s):  
Major Depression ◽  
Treatment Resistant ◽  
Open Label ◽  
Open Label Trial

scholarly journals Mirtazapine in Comorbid Major Depression and Alcohol Dependence: An Open-Label Trial

2012 ◽  
Vol 8 (3) ◽  
pp. 200-204 ◽  
Author(s):  
Jack R. Cornelius ◽  
Antoine B. Douaihy ◽  
Duncan B. Clark ◽  
Tammy Chung ◽  
D. Scott Wood ◽  
...  
Keyword(s):  
Major Depression ◽  
Alcohol Dependence ◽  
Open Label ◽  
Open Label Trial

scholarly journals “BAX602” in Preventing Surgical Adhesion after Extracorporeal Ventricular Assist Device Implantation for Refractory Congestive Heart Failure: Study Protocol for a Multicenter Randomized Clinical Trial

2020 ◽  
Vol 34 (5) ◽  
pp. 651-657
Author(s):  
Satsuki Fukushima ◽  
Koko Asakura ◽  
Toshimitsu Hamasaki ◽  
Kaori Onda ◽  
Takuya Watanabe ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Cardiac Surgery ◽  
Ventricular Assist Device ◽  
Adhesion Prevention ◽  
Open Label ◽  
Assist Device ◽  
Ventricular Assist ◽  
Device Implantation ◽  
Great Vessels

Abstract Background The high surgical risk in redo cardiac surgery is largely attributed to adhesions around the epicardium and the great vessels. BAX602 is an adhesion prevention reagent composed of two synthetic polyethylene glycols. Spraying BAX602 over the epicardium and the great vessels reportedly contributes to adhesion prevention after pediatric cardiac surgery. The present study aims to evaluate the safety and effectiveness of BAX602 spray in patients undergoing extracorporeal ventricular assist device implantation surgery to treat refractory congestive heart failure. Methods and Design This investigator-initiated, multicenter, pivotal, two-arm, open-label, randomized trial will include a total of 30 patients. The primary outcome measure is the severity of adhesions, which will be evaluated during re-sternotomy surgery performed 2–12 weeks after the primary extracorporeal ventricular assist device implantation surgery. The adhesion severity will be evaluated at five predefined sites using a four-grade adhesion evaluation score (0 = no adhesion; 1 = filmy and avascular adhesion; 2 = dense/vascular adhesion; 3 = cohesive adhesion). This measure will be summarized in two ways to evaluate the effect of BAX602: (1) the total score of the severity of adhesions at all five sites (ranging from 0 to 15), and (2) the total number of sites with dense/vascular or cohesive adhesions (ranging from 0 to 5). Ethics and Dissemination The study findings will be disseminated at regional, national, and international conferences and through peer-reviewed scientific journals. Trial Registration The trial was registered in the UMIN Clinical Trials Registry (UMIN-CTR: UMIN000038998) on 6 January 2020.

An open label trial of C-1073 (mifepristone) for psychotic major depression*

2002 ◽  
Vol 52 (5) ◽  
pp. 386-392 ◽  
Author(s):  
Joseph K Belanoff ◽  
Anthony J Rothschild ◽  
Frederick Cassidy ◽  
Charles DeBattista ◽  
Etienne-Emile Baulieu ◽  
...  
Keyword(s):  
Major Depression ◽  
Open Label ◽  
Psychotic Major Depression ◽  
Open Label Trial

Venlafaxine in Treatment-Resistant Major Depression: A Canadian Multicenter, Open-Label Trial

1999 ◽  
Vol 19 (5) ◽  
pp. 401-406 ◽  
Author(s):  
Claude de Montigny ◽  
Peter H. Silverstone ◽  
Guy Debonnel ◽  
Pierre Blier ◽  
David Bakish
Keyword(s):  
Major Depression ◽  
Treatment Resistant ◽  
Open Label ◽  
Open Label Trial

scholarly journals Early continuous ultrafiltration in Chinese patients with congestive heart failure (EUC-CHF): study protocol for an open-label registry-based prospective clinical trial

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Ying Yang ◽  
Chao Shen ◽  
Jiangting Lu ◽  
Fen Xu ◽  
Jinshan Tong ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Hospital Admission ◽  
Fluid Overload ◽  
Volume Overload ◽  
Clinical Parameter ◽  
Chinese Patients ◽  
Open Label ◽  
Electrolyte Disturbance ◽  
Treatment Groups

Abstract Background Conventional pharmacologic therapies aim to reduce fluid overload in advanced heart failure (HF) represented by intravenous (IV) loop diuretics (LDs) have sometimes not so efficacious and been reported to have side effects such as unpredictable removal of water and sodium and electrolyte disturbance. It is not certain whether early ultrafiltration (UF) is effective than LDs in relieving edema. Given the weakness of evidence for early UF in patients with fluid overload, recommendations of UF in guidelines is considered as second-line therapy only for patients with refractory congestion, who failed to respond to LD-based strategies. Methods The early continuous ultrafiltration in Chinese patients with congestive heart failure (EUC-CHF) trial is an open-label, registry-based, prospective study, recruiting patients with severe acute decompensated HF who are hospitalized for HF worsening due to overt fluid overload 24 h from hospital admission. Forty patients will be enrolled to two treatment groups (n = 20 for each group). The primary outcomes are the changes of weight loss and dyspnea severity score after treatment, as well as the occurrence of clinically overt major bleeding. Discussion EUC-CHF trial was primarily designed to evaluate the efficacy and safety of early UF in patients with acute decompensated HF to reduce volume overload and improve clinical outcome. The trial aims to determine if early UF in acute HF is superior to IV LDs in clinical parameter improvement without adverse events and prevents rehospitalization up to 30 days. Also the trial is expected to establish a scoring system based on Chinese population to guide early UF treatment in appropriate patients. EUC-CHF is one of the first controlled trials tailored to determine the benefit of UF with 24 h from hospital admission. Trial registration www.chictr.org.cn, ChiCTR1800019556. Registered on 18 November 2018.

Sign in / Sign up

Export Citation Format

Share Document